Topics

Pfizer receives positive CHMP opinion for oncology biosimilar RUXIENCE

04:42 EST 3 Feb 2020 | Pharmaceutical Business Review

RUXIENCE is a monoclonal antibody (mAb) for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA),

The post Pfizer receives positive CHMP opinion for oncology biosimilar RUXIENCE appeared first on Pharmaceutical Business review.

Original Article: Pfizer receives positive CHMP opinion for oncology biosimilar RUXIENCE

NEXT ARTICLE

More From BioPortfolio on "Pfizer receives positive CHMP opinion for oncology biosimilar RUXIENCE"

Quick Search

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...